ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Treatment Monitoring of Immunotherapy and Targeted Therapy Using
Open access · bronzeAbstract read
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0.European journal of nuclear medicine and molecular imaging · 2025Guideline
- Clinical potential of [European journal of nuclear medicine and molecular imaging · 2026Article
- Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events.Insights into imaging · 2025Article
- Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based onCancers · 2025Article
- Update to the RANO Working Group and EANO recommendations for the clinical use of PET imaging in gliomas.Neuro-oncology · 2025Article
- Imaging of brain metastases treated with immune checkpoint inhibitors.Immunotherapy · 2025Article
- Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended-Gate Field-Effect-Transistor Biosensors.Small science · 2025Article
- An effective MRI perfusion threshold based workflow to triage additionalScientific reports · 2025Article
- Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.International journal of molecular sciences · 2025Review
- Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.Neuro-oncology · 2024Review
- A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.Frontiers in immunology · 2024Review
- Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.Neuro-oncology · 2023Article
- Neurosurgical Interventions for Cerebral Metastases of Solid Tumors.Deutsches Arzteblatt international · 2023Review
- The radiological appearances of lung cancer treated with immunotherapy.The British journal of radiology · 2023Review
- Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.International journal of molecular sciences · 2023Review
- Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.Neuro-oncology · 2022Article
- Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.Advanced drug delivery reviews · 2022Review
- Review
- Brain metastases: the role of clinical imaging.The British journal of radiology · 2022Review
- The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 2 countries.
Norbert GalldiksDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany norbert.galldiks@uk-koeln.de.
Diana S Y AbdullaCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Matthias SchefflerCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Fabian WolpertDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Jan-Michael WernerDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Martin HüllnerDepartment of Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland.
Gabriele StoffelsInstitute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
Viola SchweinsbergCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Max SchlaakCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Nicole KreuzbergCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Jennifer LandsbergCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Philipp LohmannInstitute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
Garry CecconDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Christian BauesCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Maike TrommerCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Eren CelikCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Maximilian I RugeCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Martin KocherInstitute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
Simone MarnitzCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Gereon R FinkDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jörg-Christian TonnDepartment of Neurosurgery, University Hospital LMU Munich, Munich, Germany; and.
Michael WellerDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Karl-Josef LangenInstitute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
Jürgen WolfCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
Cornelia MauchCenter of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
University Hospital Cologne · DEUniversity of Cologne · DEForschungszentrum Jülich · DEUniversity of Zurich · CHLMU Klinikum · DEUniversity Hospital Bonn · DEUniversity Hospital of Zurich · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the value of
Indexed as
ImmunotherapyAdultAgedAged, 80 and overBrain NeoplasmsCombined Modality TherapyDisease ProgressionFemaleHumansLung NeoplasmsMaleMelanomaMiddle AgedMolecular Targeted TherapyRetrospective StudiesTreatment Outcome(18F)fluoroethyltyrosineTyrosinecheckpoint inhibitorspseudoprogressionradionecrosisresponse assessmenttreatment-related changes
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.